Trial Profile
A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2014
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors MAP Pharmaceuticals
- 28 Jun 2007 New trial record.